Questions

Translational medicine is a highly interdisciplinary field, the primary goal of which is to coalesce assets of various natures, combine disciplines, resources, expertise, and techniques, within the individual pillars in order to improve the global healthcare system significantly.

Precision medicine, is a medical model that separates people into different groups – with medical decisions, practices, interventions and/or products being tailored to the individual patient based on their predicted response or risk of disease.

Cell therapy (cell treatment) – the direction of modern medicine, which uses stem cells of various origins and types to treat many diseases and pathological conditions, and develops new schemes and methods for their treatment. The main indications for stem cell treatment are diseases or pathological conditions, as a result of which the number of healthy cells of the body necessary for its normal working and functioning is reduced.

Stem cells are cells that can differentiate into other types of cells, and can also divide in self-renewal to produce more of the same type of stem cells.

Bone marrow, adipose tissue, peripheral blood, cord blood, umbilical cord, placenta, amniotic fluid and abortive material.

That, like a stem cell, has a tendency to differentiate into a specific type of cell, but is already more specific than a stem cell and is pushed to differentiate into its “target” cell.

In an adult, the number of stem cells and their potential for reproduction and growth are noticeably lower than in fetal tissue. In addition, adult stem cells have pronounced and formed histocompatibility antigens on their membranes, which requires the selection of a donor to the recipient, as in organ transplantation. In adult stem cell transplantation, pre-transplant medication and immunosuppressive therapy after transplantation is required to suppress the rejection reaction. Adult stem cells are more differentiated and are not pluripotent (the ability to differentiate into all types of cells), which means that their ability to transform into certain cells and tissues is limited.

Human cord blood is cryopreserved at the birth of a child aged 35-42 weeks. Cord blood contains a large number of specialized, differentiated cells and blood cells with their own antigenic structure.

The potential for reproduction and growth in polypotent cord blood cells is lower than in adaptive polyvalent cell complex.

The concentration of stem cells in cord blood is an order of magnitude lower than in our preparation containing adaptive polyvalent cell complex.

Donor cord blood transplantation also requires pre-transplant drug preparation and immunosuppressive therapy to suppress the rejection reaction.

The list of contraindications is mainly associated with the presence in patients of acute and emergency conditions in which there are restrictions on the use of immunotherapy and / or cell therapy.

The list of contraindications is mainly associated with the presence of acute and urgent conditions in patients in which there are restrictions on the use of immunotherapy and / or cell therapy.

However, after stabilization or remission for several days to 6 months, depending on the disease, treatment with the help of highly effective adaptive polyvalent cell complexes aimed at quick recovery and rehabilitation is recommended.

Therapeutic contraindications:

Vasculitis in the exacerbation phase: capillaritis, phlebitis, arteritis: transplantation after remission, no earlier than three months, is possible;
Acute thrombosis: transplantation is possible not earlier than 3-6 months;
Fresh hemorrhages in the area of the eye: treatment is possible after 3 months;
Severe hypertension of the pulmonary circulation associated with vasculitis, thrombosis, large focal pneumonia, accompanied by the development of an acute or subacute pulmonary heart;
The terminal stage of the disease (severe intoxication, profound metabolic disorders, severe decompensation of internal organs).

Cardiological contraindications:

Acute myocardial infarction (treatment is possible when the patient can be transported with normalization of blood troponin levels);
Acute myocarditis;
Acute pericarditis;
Acute endocarditis.
Increased blood pressure in erythremia;
Unstable angina (treatment is possible only after reperfusion of any origin);
Pulmonary embolism;
Relapse of chronic pulmonary thromboembolism;

Neurological contraindications:

Acute hemorrhagic type of cerebral circulation, including subarachnoid hemorrhage, acute period up to 4-6 months.
Acute cerebrovascular accident according to ischemic type, the sharpest period is up to 9 days.
Acute viral encephalitis, meningitis.
Multiple sclerosis in the acute stage (treatment should not be carried out in the acute period).
Spinal injury (therapy is possible after 2-3 months after the injury, provided the patient is transportable).
Inflammatory diseases of the nervous system in the acute stage.
Epilepsy (treatment is possible with a controlled course of the disease, established anticonvulsant therapy).
Convulsive syndrome of any etiology (treatment is possible with a controlled course of the disease, established anticonvulsant therapy).

There are also contraindications associated with diseases that can be found in the process of diagnosis or analysis of a medical statement.

The Progenitor stem cells included in the adaptive multivalent cell complex have the greatest potential for division, growth and specialization among all other types of stem cells that can be used for treatment. They are most effective for the treatment of diseases and pathological conditions, as a result of which the number of healthy cells necessary for the normal functioning of organs and systems is reduced in the body. Treatment with progenitor stem cells is recommended for a large number of diseases characterized by varying degrees of dystrophy, damage to tissues, organs and systems at the cellular level.

Our long-term experience in research and clinical practice has shown the high efficiency of biogenic placental factors and adaptive multivalent cell complex in the treatment of the most serious human diseases and pathological conditions, including multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer’s and Parkinson’s disease, stroke, craniocerebral and spinal cord injury, military injuries, trophic ulcers, burns and frostbite, erectile dysfunction, type 1 and type 2 diabetes, myocardial disease, heart failure, autoimmune and genetic diseases, blood sores, etc.

The unique properties of progenitor stem cells, which allow to restore and maintain the body, create new tissues to replace irreversibly damaged ones, give hope to many patients whose diseases have been considered incurable for many years. And progenitor stem cells are extremely effective in the fight against aging.

Application protocols Progenitor Stem Cells or biogenic placental factors and adaptive polyvalent cellular complex were developed by professionals based on the company’s high standards and international requirements.

The duration of the course of treatment using the recommended cell products ranges from 3 to 5 days and depends on the diagnosis, medical history, complications and concomitant diseases. To inform the patient about the time required for treatment, we ask you to provide basic medical information.

Cellular products in accordance with the selected program and the recommended protocol are administered intramuscularly, intravenously or subcutaneously, in certain body cavities, most often in the frontal part of the abdomen.

For some pathologies, other methods of drug administration are recommended – intrathecally (under the lining of the brain) or epidurally (administration of drugs at the L4-L5 level of the lumbar vertebrae).

This procedure is not surgical, is performed by a doctor, and is well tolerated by patients.

Since the routes of administration of cellular products are minimally invasive, rehabilitation after our course of treatment is not required.

In most cases, this is an outpatient treatment that takes 3-4 hours a day. At the same time, during treatment, relatives of the patient accompanying the patient, or his or her discussing staff can be in the ward with the patient, providing him with psychological or other support. If the patient’s condition requires inpatient treatment and round-the-clock monitoring during the periods before treatment and after the introduction of the recommended cellular products, the patient is in the clinic for the entire time of the visit.

The cost of treatment depends on the diagnosis, quantity and type of drug containing of progenitor stem cells or/and biogenic placental factors or/and adaptive multivalent cell complexes that will be used to treat the patient. It includes the actual treatment with certain cellular preparations and other products, medical examinations and consultations in the clinic, airport-hotel-airport transfer and daily hotel-clinic-hotel transfer.